Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabometyx in advanced RET-rearranged NSCLC
NCT04131543Phase 2Unknown
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoint: Response Rate at 24 months. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04131543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131543.